Anika Therapeutics (ANIK) Equity Average (2016 - 2025)
Historic Equity Average for Anika Therapeutics (ANIK) over the last 15 years, with Q3 2025 value amounting to $147.2 million.
- Anika Therapeutics' Equity Average fell 2453.22% to $147.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.2 million, marking a year-over-year decrease of 2453.22%. This contributed to the annual value of $183.1 million for FY2024, which is 2642.96% down from last year.
- Anika Therapeutics' Equity Average amounted to $147.2 million in Q3 2025, which was down 2453.22% from $148.0 million recorded in Q2 2025.
- In the past 5 years, Anika Therapeutics' Equity Average registered a high of $288.6 million during Q4 2021, and its lowest value of $147.2 million during Q3 2025.
- In the last 5 years, Anika Therapeutics' Equity Average had a median value of $274.5 million in 2021 and averaged $240.8 million.
- As far as peak fluctuations go, Anika Therapeutics' Equity Average skyrocketed by 433.76% in 2022, and later plummeted by 3084.36% in 2024.
- Over the past 5 years, Anika Therapeutics' Equity Average (Quarter) stood at $288.6 million in 2021, then dropped by 1.15% to $285.2 million in 2022, then dropped by 15.38% to $241.4 million in 2023, then plummeted by 30.84% to $166.9 million in 2024, then decreased by 11.79% to $147.2 million in 2025.
- Its Equity Average was $147.2 million in Q3 2025, compared to $148.0 million in Q2 2025 and $151.2 million in Q1 2025.